Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
Open Access
- 1 August 2016
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (8) , 1424-1430
Abstract
No abstract availableKeywords
Funding Information
- Otsuka Pharmaceutical Co, Ltd, Japan
- Public Health Service Grant
- National Cancer Institute (5U24-CA076518)
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- NHLBI (5U10HL069294)
- NCI
- Health Resources and Services Administration (HHSH250201200016C)
- Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028)
- Alexion
- *Amgen, Inc
- Anonymous donation to the Medical College of Wisconsin
- Be The Match Foundation
- *Bristol Myers Squibb Oncology
- *Celgene Corp
- *Chimerix, Inc
- Fred Hutchinson Cancer Center
- Gamida Cell Ltd
- Genentech, Inc
- Genzyme Corp
- *Gilead Sciences, Inc
- Health Research, Inc.
- Roswell Park Comprehensive Cancer Center
- HistoGenetics, Inc
- Incyte Corp
- *Jazz Pharmaceuticals, Inc
- Jeff Gordon Children's Foundation
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co, Inc
- Mesoblast
- *Millennium: The Takeda Oncology Co
- *Miltenyi Biotec, Inc
- National Marrow Donor Program
- Neovii Biotech NA, Inc
- Novartis Pharmaceuticals Corp
- Onyx Pharmaceuticals
- Optum Healthcare Solutions, Inc
- Otsuka America Pharmaceutical, Inc
- Otsuka Pharmaceutical Co, Ltd–Japan
- Oxford Immunotec
- PerkinElmer, Inc
- Pharmacyclics
- *Sanofi US
- Seattle Genetics
- Sigma-Tau Pharmaceuticals
- *Spectrum Pharmaceuticals, Inc
- St. Baldrick's Foundation
- *Sunesis Pharmaceuticals, Inc
- Swedish Orphan Biovitrum, Inc
- Telomere Diagnostics, Inc
- TerumoBCT
- THERAKOS, Inc
- University of Minnesota
- *Wellpoint, Inc.
This publication has 37 references indexed in Scilit:
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and CyclophosphamideTransplantation and Cellular Therapy, 2008
- New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2Bone Marrow Transplantation, 2007
- Pharmacokinetics of Once-Daily IV Busulfan as Part of Pretransplantation Preparative Regimens: A Comparison with an Every 6-Hour Dosing ScheduleTransplantation and Cellular Therapy, 2007
- Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSBlood, 2004
- Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cellsBlood, 2003
- Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomesTransplantation and Cellular Therapy, 2002
- Cellular and Clinical Pharmacology of FludarabineClinical Pharmacokinetics, 2002
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983